289 related articles for article (PubMed ID: 26185376)
21. Pre-activation with TLR7 in combination with thioridazine and loratadine promotes tumoricidal T-cell activity in colorectal cancer.
Lin X; Zhang J; Wang X; Lin G; Chen T
Anticancer Drugs; 2020 Nov; 31(10):989-996. PubMed ID: 32694422
[TBL] [Abstract][Full Text] [Related]
22. Development of an oral DNA vaccine against MG7-Ag of gastric cancer using attenuated salmonella typhimurium as carrier.
Guo CC; Ding J; Pan BR; Yu ZC; Han QL; Meng FP; Liu N; Fan DM
World J Gastroenterol; 2003 Jun; 9(6):1191-5. PubMed ID: 12800222
[TBL] [Abstract][Full Text] [Related]
23. Gastric cancer-derived heat shock protein-gp96 peptide complex enhances dendritic cell activation.
Lu WW; Zhang H; Li YM; Ji F
World J Gastroenterol; 2017 Jun; 23(24):4390-4398. PubMed ID: 28706421
[TBL] [Abstract][Full Text] [Related]
24. Conjugation of a TLR7 agonist and antigen enhances protection in the S. pneumoniae murine infection model.
Vecchi S; Bufali S; Uno T; Wu T; Arcidiacono L; Filippini S; Rigat F; O'Hagan D
Eur J Pharm Biopharm; 2014 Jul; 87(2):310-7. PubMed ID: 24434202
[TBL] [Abstract][Full Text] [Related]
25. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
26. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses.
Jackson DC; Lau YF; Le T; Suhrbier A; Deliyannis G; Cheers C; Smith C; Zeng W; Brown LE
Proc Natl Acad Sci U S A; 2004 Oct; 101(43):15440-5. PubMed ID: 15489266
[TBL] [Abstract][Full Text] [Related]
27. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
28. Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells.
Morrison BJ; Steel JC; Morris JC
BMC Cancer; 2018 Apr; 18(1):469. PubMed ID: 29699516
[TBL] [Abstract][Full Text] [Related]
29. Toll-like receptor 3 agonist complexed with cationic liposome augments vaccine-elicited antitumor immunity by enhancing TLR3-IRF3 signaling and type I interferons in dendritic cells.
Wang C; Zhuang Y; Zhang Y; Luo Z; Gao N; Li P; Pan H; Cai L; Ma Y
Vaccine; 2012 Jul; 30(32):4790-9. PubMed ID: 22634298
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model.
Ito H; Ando T; Arioka Y; Saito K; Seishima M
Immunology; 2015 Apr; 144(4):621-30. PubMed ID: 25322876
[TBL] [Abstract][Full Text] [Related]
31. Targeted Activation of Toll-Like Receptors: Conjugation of a Toll-Like Receptor 7 Agonist to a Monoclonal Antibody Maintains Antigen Binding and Specificity.
Gadd AJ; Greco F; Cobb AJ; Edwards AD
Bioconjug Chem; 2015 Aug; 26(8):1743-52. PubMed ID: 26133029
[TBL] [Abstract][Full Text] [Related]
32. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
[TBL] [Abstract][Full Text] [Related]
33. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
Homma S; Komita H; Sagawa Y; Ohno T; Toda G
Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
[TBL] [Abstract][Full Text] [Related]
34. Immunization with murine breast cancer cells treated with antisense oligodeoxynucleotides to type I insulin-like growth factor receptor induced an antitumoral effect mediated by a CD8+ response involving Fas/Fas ligand cytotoxic pathway.
Schillaci R; Salatino M; Cassataro J; Proietti CJ; Giambartolomei GH; Rivas MA; Carnevale RP; Charreau EH; Elizalde PV
J Immunol; 2006 Mar; 176(6):3426-37. PubMed ID: 16517711
[TBL] [Abstract][Full Text] [Related]
35. Antitumor activity of expanded human tumor-infiltrating gammadelta T lymphocytes.
Chen J; Niu H; He W; Ba D
Int Arch Allergy Immunol; 2001 Jul; 125(3):256-63. PubMed ID: 11490159
[TBL] [Abstract][Full Text] [Related]
36. Self-assembling peptide for co-delivery of HIV-1 CD8+ T cells epitope and Toll-like receptor 7/8 agonists R848 to induce maturation of monocyte derived dendritic cell and augment polyfunctional cytotoxic T lymphocyte (CTL) response.
Ding Y; Liu J; Lu S; Igweze J; Xu W; Kuang D; Zealey C; Liu D; Gregor A; Bozorgzad A; Zhang L; Yue E; Mujib S; Ostrowski M; Chen P
J Control Release; 2016 Aug; 236():22-30. PubMed ID: 27297778
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of subcutaneous growth of Ehrlich ascites carcinoma (EAC) tumor by post-immunization with EAC-cell gangliosides and its anti-idiotype antibody in relation to tumor angiogenesis, apoptosis, cell cycle and infiltration of CD4+, CD8+ lymphocytes, NK cells, suppressor cells and APC-cells in tumor.
Mondal B; Saha S
Indian J Exp Biol; 2011 Aug; 49(8):574-84. PubMed ID: 21870425
[TBL] [Abstract][Full Text] [Related]
38. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
[TBL] [Abstract][Full Text] [Related]
39. Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity.
Vo MC; Lee HJ; Kim JS; Hoang MD; Choi NR; Rhee JH; Lakshmanan VK; Shin SJ; Lee JJ
Oncotarget; 2015 Oct; 6(32):33781-90. PubMed ID: 26418952
[TBL] [Abstract][Full Text] [Related]
40. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
